TOKYO, May 23, 2011 /CNW/ - Sosei Group Corporation ("Sosei"; TSE
Mothers Index: 4565), the biopharmaceutical company, today announced
that Sosei Co., Ltd., its wholly owned Japanese subsidiary, will launch
its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, tomorrow
24 May, through the distribution network of its commercialization
partner, ASKA Pharmaceutical Co., Ltd.
NorLevo(R) is an oral emergency contraceptive, which is taken within 72
hours after unprotected sexual intercourse or contraceptive failure to
prevent unwanted pregnancy. Its active ingredient, levonorgestrel, is
listed as an essential drug by WHO.
Sosei acquired the exclusive development and distribution rights to the
product in Japan and Australia from Laboratoire HRA Pharma in April
2001. NorLevo(R) was first launched in Europe in 1999 and is currently
approved in some 50 countries. In Japan, Sosei was granted approval for
NorLevo(R) in February 2011.
Sosei signed a distribution agreement with ASKA Pharmaceutical Co., Ltd
in November 2009.
Shinichi Tamura, CEO of Sosei Group Corporation, commented: "We are very
pleased to announce the launch of the first emergency contraceptive in
Japan. We are proud that our first product has reached the market and
that we can contribute to the health of Japanese women. These are
important achievements for our company. Sosei will continue with its
efforts to fulfil unmet medical needs in future."
Notes for Editors:
Sosei is an international biopharmaceutical company anchored in Japan
with a global reach. It practises a reduced risk business model by
acquiring compounds from, and bringing compounds into, Japan through
exploitation of its unique position within global markets. For further
information about Sosei, please visit http://www.sosei.com.
About HRA Pharma
HRA Pharma is a privately-held European pharmaceutical company that
designs products, devices and supporting services in niche areas of
health and makes them available to doctors and patients worldwide. The
company targets therapeutic gaps in the areas of reproductive health
and endocrinology and uses innovative marketing solutions and
socially-conscious programs to promote healthy management of drugs and
diseases. Headquartered in Paris, France and with offices throughout
Europe, HRA Pharma has built a strong network of R&D, manufacturing,
distribution and NGO partners which enables it to satisfy critical
patient needs and improve patient health in over 50 countries across
the globe. Visit http://www.hra-pharma.com for more information.
Based on the corporate mission, "Contribute toward the improvement of
people's health and progress in medicine through the development of
innovative products," ASKA Pharmaceutical, as a focused research and
development (R&D) oriented company, concentrates its management
resources for the development of new products in defined areas to
develop and supply innovative and creative pharmaceutical products that
contribute broadly to society. With 934 employees (as of December
2010), ASKA develops and commercializes products in areas of internal
medicine (digestive and cardiovascular organs, thyroid glands),
urology, otorhinolaryngology, and gynecology and obstetrics. For
further information about ASKA, please visit http://www.aska-pharma.co.jp.
SOURCE Sosei Group Corporation
For further information:
Enquiries: Sosei Group Corporation: Tokyo Office: Milica STOJKOVIC, Investor Relations, +81-(0)3-5210-3399, email@example.com; London Office: Kathryn LYDON, PA to CEO & Corporate Communication, +44-(0)20-7691-0983, firstname.lastname@example.org